相似文献
1
The big gap at the FDA.
Fortune. 2002 Jul 22;146(2):113-4, 116.
2
What ails the FDA?
N Engl J Med. 2005 Mar 17;352(11):1063-6. doi: 10.1056/NEJMp058003.
3
FDA embraces risk-management approach.
Nat Biotechnol. 2003 Oct;21(10):1120-1. doi: 10.1038/nbt877.
4
FDA restructures new product review centers.
Nat Biotechnol. 2002 Oct;20(10):960. doi: 10.1038/nbt1002-960a.
5
Muddied messages about FDA.
Nat Biotechnol. 2003 Jul;21(7):732-3. doi: 10.1038/nbt0703-732.
6
Should you let the FDA decide what drugs you pay for?
Bus Health. 1996 Oct;14(10):65, 69-70, 73.
7
McClellan's FDA: boon to industry, consumers, or both? New FDA chief plans to speed drug approval and reduce costs.
Lancet. 2003 Aug 2;362(9381):379-80. doi: 10.1016/s0140-6736(03)14063-9.
8
Confronting the future of the FDA.
Natl J (Wash). 1996 Dec 14;28(50):2704-5.
9
The impact of FDA reform.
Med Device Technol. 2003 Apr;14(3):36-7.
10
Women's health and the FDA.
N Engl J Med. 2005 Oct 20;353(16):1650-1. doi: 10.1056/NEJMp058225.
Zotero 插件